Skip to main content
Blog | Development

How EVOQ platform technology scales metamaterials for cost-effective product innovation

EVOQ, Staff writer at EVOQ
EVOQ Staff writer
Aug 4, 2025

Introduction

Industries face escalating costs and risks when scaling material solutions for new products. Unstable processes and inconsistent outcomes limit innovation, delay market entry, and erode competitive edges. EVOQ platform technology addresses these challenges by delivering scalable, cost-effective metamaterials that empower innovators to create new products, enhance existing ones, and invent novel applications. With trials demonstrating stability and cost reductions, EVQ-218 transforms product development in sectors like healthcare, medical devices, and textiles. This post explores how EVOQ scales efficiently, ensures precision, and drives measurable ROI for executives seeking long-term impact.

Why scalability matters for innovation

Efficient scaling defines the future of product innovation. Traditional material solutions often falter under high-volume demands, leading to costly delays and unreliable performance. For industries like healthcare, medical devices, textiles, and energy, scalability ensures rapid prototyping, cost savings, and market leadership. Solution requirements demand processes that handle large-scale production without compromising quality or increasing risks. The EVOQ platform technology meets these needs by streamlining production, reducing costs, and enabling innovators to bring new products to market faster, such as antimicrobial coatings for catheters or sustainable fabrics for apparel.

How EVQ-218 delivers scalable solutions

EVQ-218, a medical-grade silver metamaterial, empowers industries with cost-effective, high-volume production processes. Unlike silver-based competitors, which struggle with inconsistent scaling and agglomeration, EVOQ produces uniform, nanoscale metamaterials that maintain stability across applications. Key features include:

  • Scalable processes: Streamlined production reduces costs by up to 500x, enabling rapid innovation cycles.
  • Consistent nanoscale sizes: Uniformly-sized material ensures reliable outcomes for new product designs.
  • Non-ionic stability: Prevents agglomeration, ensuring consistency and durability in high-volume settings.

Precision for reliable product development

Scalability pairs with precision in EVOQ platform technology. Consistent, and narrow, size distribution ensure accuracy in applications, from medical devices to textile surfaces. Traditional materials often vary in size, leading to performance issues that delay product launches. EVQ-218’s perfect spherical shapes deliver predictable outcomes, enabling innovators to enhance existing products or invent novel uses. In textiles, FUZE F1 integrates EVOQ metamaterial to create durable, antimicrobial fabrics for major brands, improving product longevity and meeting global standards without added costs.

Driving ROI through cost savings

Executives prioritize ROI when adopting new technologies. EVOQ platform technology delivers measurable returns by reducing production costs and risks. Tests show significant savings through:

  • Lower material waste: Scalable processes minimize excess, unlike traditional methods.
  • Faster market entry: Streamlined production accelerates development timelines.
  • Regulatory compliance: Non-ionic, stable metamaterials meet FDA and EPA standards, reducing approval delays.

Allied Feather + Down, the global leader in down products, used FUZE technology from EVOQ to create ExpeDRY. ExpeDRY works through a permanent and chemical-free bonding of non-toxic gold metamaterial to the down cluster which aid in the evaporation of water molecules, causing the down to dry faster and stay dry in high humidity and extreme conditions. There is nothing like it on the market today and it was made possible by the EVOQ platform technology.

Overcoming competitive barriers

Unlike other technologies, which face agglomeration, ion release, and inconsistent sizing, the EVOQ platform technology combines scalability, precision, safety, and stability. Further, common silvers rupture bacterial cell walls, risking antimicrobial resistance (AMR), while EVQ-218 sequesters sulfur to disrupt bacterial metabolism without triggering AMR. This advancement in the war against antimicrobial resistance, empowers executives to invest confidently in technologies that scale with industry demands, supporting a wide range of healthcare applications with reliable, cost-effective solutions.

Conclusion

The EVOQ platform technology redefines product innovation by delivering scalable, cost-effective metamaterials. With EVQ-218, industries achieve precision, safety, and stability, overcoming barriers to create new products and enhance existing ones in healthcare, textiles, and beyond. The data positions EVOQ as a leader in empowering innovators. Explore how the EVOQ platform technology scales solutions for your industry—request more information today.